Colorectal Cancer is the third most common cancer without
counting different skin cancers. It’s also the third leading cause of
cancer-related death in the United States for both men and women.
To combat this disease, doctors came together to start “The Preventing Adenomas of the Colon with Eflornithine & Sulinidac” or PACES, a screening option which has been proven to reduce mortality.
Those diagnosed with colorectal cancer then have an increased risk for developing a new colon cancer. By taking one (or both) of this drug regularly, the patient will experience a lower risk of having a “second primary colorectal cancer or adenoma” which is a possibly precancerous polyp on the colon.
Eflornithine actually slows down the body’s polyamine production.
Sulindac can then help get rid of extra polyamines.
Thanks to genomic technology, patients with a greater risk of recurrence can be recognized earlier and put on the treatment.
Patients taking these drugs “lowered their risk of developing another adenoma over the next three years to less than one third of what it was for those who did not take the drugs,” while also lowering existing adenomas by 90%.
This is currently one of the largest cancer clinical trials in the United States. For more information, click here for the article from Cancer.gov.
For more information about colorectal cancer and treatment options, please call us today!